摘要
目的探讨恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎并脂肪肝的临床疗效。方法选取青岛市城阳区人民医院2016年5月-2018年5月收治的慢性乙型肝炎并脂肪肝患者100例,采用单盲法分为对照组与观察组,各50例。对照组患者予以恩替卡韦分散片治疗,治疗组患者在对照组基础上联合水飞蓟宾胶囊治疗,两组患者均以3个月为1个疗程。比较两组患者治疗前后肝功能指标〔丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、乙型肝炎病毒-DNA(HBV-DNA)〕、血脂指标〔总量固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)及低密度脂蛋白胆固醇(LDL-C)〕及临床疗效,并观察两组患者不良反应发生情况。结果治疗前两组患者AST、ALT、HBV-DNA、TC、TG、HDL-C及LDL-C比较,差异无统计学意义(P>0.05);治疗后观察组患者AST、ALT及HBV-DNA、TC、TG及LDL-C低于对照组,HDL-C高于对照组(P<0.05)。观察组患者临床疗效优于对照组,不良反应发生率低于对照组(P<0.05)。结论恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎并脂肪肝的临床疗效确切,可有效改善患者肝功能和血脂代谢,且安全性较高。
Objective To observe the clinical efficacy of entecavir combined with silybin for chronic hepatitis B complicated with fatty liver.Methods A total of 100 cases of patients with chronic hepatitis B complicated with fatty liver were selected from May 2016 to May 2018 in Chengyang District people’s Hospital,which were randomly divided into control group(n=50)and observation group(n=50)by single blind method.The control group was treated with entecavir dispersible tablets,the treatment group was treated with silybin capsule based on the control group,both groups were treated with 3 months as a course of treatment.Liver function index(ALT、AST、HBV-DNA),blood lipid index(TC、TG、HDL-C及LDL-C)before and after treatment,and clinical effect were compared between the two groups,and the incidence of adverse reactions were observed.Results There was no significant differences in AST,ALT,HBV-DNA,TC,TG,HDL-C or LDL-C between the two groups before treatment(P>0.05).After treatment,the observation group of AST,ALT,HBV-DNA,TC,TG and LDL-C were lower than control group,and HDL-C was higher than control group(P<0.05).The clinical effect of observation group was better than control group,and the incidence rate of adverse reactions was lower than control group(P<0.05).Conclusion Entecavir combined with silybin have an exact clinical effect for chronic hepatitis B complicated with fatty liver,it can effectively improve the liver function and blood lipid level of the patients,and with high safety.
作者
赵波
戚永花
万强
ZHAO Bo;QI Yong-hua;WAN Qiang(Department of Infectious Diseases,Chengyang District people's Hospital,Qingdao 266109,China)
出处
《临床合理用药杂志》
2019年第15期23-25,共3页
Chinese Journal of Clinical Rational Drug Use
